Quantcast
Environmental News for a Healthier Planet and Life

Help Support EcoWatch

WHO Suspends Trial of Trump-Touted COVID-19 Treatment Hydroxychloroquine Due to Safety Concerns

Health + Wellness
WHO Suspends Trial of Trump-Touted COVID-19 Treatment Hydroxychloroquine Due to Safety Concerns
A pharmacy tech pours out pills of hydroxychloroquine at Rock Canyon Pharmacy in Provo, Utah, on May 20, 2020. GEORGE FREY / AFP via Getty Images

Citing safety concerns, the World Health Organization (WHO) said Monday it was suspending its trial of hydroxychloroquine, an anti-malarial drug that has been championed by President Donald Trump as a treatment for the new coronavirus.


The WHO decision followed the release of a Lancet study Friday that found that COVID-19 patients who took the drug were more likely to die or develop heart problems.

"The steering committee met over the weekend, in the light of this uncertainty," WHO chief scientist Soumya Swaminathan told NPR. "We decided we should be proactive, err on the side of caution and suspend enrollment temporarily into the hydroxychloroquine arm [of the Solidarity trial]."

The WHO Solidarity Trial is an effort to test the effectiveness of potential COVID-19 treatments, including hydroxychloroquine, remdesivir and an HIV combination therapy, The Guardian reported. It involves 3,500 patients from 17 countries randomly assigned one of four experimental treatments, according to NPR.

Unlike the WHO trial, the Lancet study was based on observation rather than a controlled experiment. However, the number of people in the study — 96,000 — raised concerns, Swaminathan explained to NPR.

Of the 96,000 in the Lancet study, nearly 15,000 were given hydroxychloroquine or chloroquine, with or without an antibiotic, BBC News reported. The death rate for patients treated with hydroxychloroquine was double the control, at 18 percent compared to nine percent. The death rate for patients treated with chloroquine was 16.4 percent.

In light of these findings, the Executive Group of the Solidarity Trial met Saturday and agreed to a temporary pause of WHO's hydroxychloroquine trial, WHO Director-General Tedros Adhanom Ghebreyesus told reporters Monday.

"The review will consider data collected so far in the Solidarity Trial and, in particular robust randomised available data, to adequately evaluate the potential benefits and harms from this drug," he said.

Swaminathan told NPR that WHO would decide whether to resume the hydroxychloroquine tests in a week or two.

In the meantime, Tedros said the other arms of the Solidarity Trial were continuing, and that concerns about hydroxychloroquine were limited to its use as a COVID-19 treatment.

"I wish to reiterate that these drugs are accepted as generally safe for use in patients with autoimmune diseases or malaria," he said.

The news came the day after Trump claimed to have "just finished" a course of hydroxychloroquine as a preventative measure against the new coronavirus in an interview aired on Sinclair Broadcasting, as CNBC reported.

"And by the way, I'm still here," he said.

Trump first began to promote the use of hydroxychloroquine against the new coronavirus in March, but the Lancet study is not the first to question its safety as a treatment for the new disease.

Studies published in April found that hydroxychloroquine taken with the antibiotic azithromycin could increase the risk of heart failure, and that U.S. Veterans Health Administration patients treated with hydroxychloroquine had higher death rates than those who were not.

The WHO trial itself had not produced any data showing increased risk from hydroxychloroquine before it was suspended, Swaminathan told NPR.

The White House declined to comment to CNBC on WHO's decision to suspend the trial, and the Department of Health and Human Services did not respond in time.

People Have the Power - VOTE 2020

Climate-action nonprofit Pathway to Paris first launched in 2014 with an "intimate evening" of music and conversation after the People's Climate March in New York City.

Read More Show Less

EcoWatch Daily Newsletter

Heo Suwat Waterfall in Khao Yai National Park in Thailand. sarote pruksachat / Moment / Getty Images

A national park in Thailand has come up with an innovative way to make sure guests clean up their own trash: mail it back to them.

Read More Show Less

Trending

The 2020 presidential election poses a critical test of climate conservatives' willingness to put their environmental concerns before party politics. filo / Getty Images

By Ilana Cohen

Four years ago, Jacob Abel cast his first presidential vote for Donald Trump. As a young conservative from Concord, North Carolina, the choice felt natural.

But this November, he plans to cast a "protest vote" for a write-in candidate or abstain from casting a ballot for president. A determining factor in his 180-degree turn? Climate change.

Read More Show Less
Headquarters of the World Health Organization in Geneva amid the COVID-19 outbreak on Aug. 17, 2020. FABRICE COFFRINI / AFP via Getty Images

The World Health Organization (WHO) announced Monday that 64 high-income nations have joined an effort to distribute a COVID-19 vaccine fairly, prioritizing the most vulnerable citizens, as Science reported. The program is called the COVID-19 Vaccines Global Access Facility, or Covax, and it is a joint effort led by the WHO, the Coalition for Epidemic Preparedness Innovations (CEPI) and Gavi, the Vaccine Alliance.

Read More Show Less
Exterior of Cold Tube demonstration pavilion. Lea Ruefenacht

By Gloria Oladipo

In the face of dangerous heat waves this summer, Americans have taken shelter in air conditioned cooling centers. Normally, that would be a wise choice, but during a pandemic, indoor shelters present new risks. The same air conditioning systems that keep us cool recirculate air around us, potentially spreading the coronavirus.

Read More Show Less

Support Ecowatch